Navigation Links
Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
Date:4/23/2008

stics of the original human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.

We leverage our preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits us to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.

Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-KSB for the fiscal year ended April 30, 2007 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
4. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
5. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Carrington Completes $8 Million Financing
8. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
9. New Brunswick Scientific Completes Merger Transaction with Eppendorf
10. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
11. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 ... is designed to introduce cutting edge communication technology, ... of platform upgrades. This webinar series demonstrates online ... quest to leverage web conferencing’s most innovative and ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... BioTime, Inc. (OTCBB:BTIM) announced today that Robert N. ... of Directors. Dr. Butler is the founder, Chief ... Center-USA, a non-profit international research, policy, and education ... live longer and better, and advise society on ...
... service revenue grows approximately 33% ... - Operating margin of 9.9% ... ... 6 PAREXEL International,Corporation (Nasdaq: PRXL ) today announced its financial results for the,fourth quarter and ...
... BioSciences announced,today the successful acquisition of funding ... the development of a long lasting, safe, ... a consortium of,microbicide researchers from four major ... from the portfolio of microbicides,being developed by ...
Cached Biology Technology: Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc. 2 Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc. 3 Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc. 4PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 2PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 3PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 4PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 5PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 6PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 7PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 8PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 9PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 10PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 11PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 12PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 13PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 14ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission 2ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission 3
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" report ... Facial recognition is a technology used ... the overall facial feature of a person such as ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... offering. One major trend emerging in ... Multimodal biometric systems utilize more than one characteristic of ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... in Spanish . Xabier Basogain Olabe ... Engineering in Bilbao, is leading this project, known as Bonis. ... visual monitoring of epidemiology in isolated areas of Paraguay and ... practical trials will begin shortly and it is hoped to ...
... Two genes have been associated with autistic spectrum ... Researchers writing in BioMed Central,s newly launched journal ... for two brain proteins, LRRN3 and LRRTM3, were significantly ... the Wellcome Trust Centre for Human Genetics, University of ...
... twist. No small feat. Now the flexible and stretchable ... heart with better resolution and speed than that of ... the University of Illinois at Urbana-Champaign and the University ... silicon electronics device used for a medical application. The ...
Cached Biology News:University of the Basque Country develops system for identifying illnesses in Paraguay 2University of the Basque Country develops system for identifying illnesses in Paraguay 3Hugging the heart electronically 2Hugging the heart electronically 3
...
...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
Biology Products: